Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland, 00100
- ARTES Psykiatrinen Palvelukeskus Oy (Mederon Ltd.)
-
Kuopio, Finland, 70110
- Savon Psykiatripalvelu Oy
-
Oulu, Finland, 90100
- Oulu Mentalcare Oy
-
Pori, Finland, 28130
- Satakunnan Psykiatripalvelu Oy at Mehiläinen Pori
-
Tampere, Finland, 33200
- Psykiatri- ja psykologikeskus Mentoria
-
-
-
-
-
Belchatow, Poland, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bydgoszcz, Poland, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdańsk, Poland, 80-438
- Indywidualna Specijalistyczna Praktyka Lekarska Wiesław Jerzy Cubała
-
Leszno, Poland, 64-100
- Nzop Mentis
-
Szczecin, Poland, 70-480
- Zachodniopomorski Instytut Psychoterapii
-
-
-
-
-
Moscow, Russian Federation, 115522
- Mental Health Research Center, Department #6
-
Saint Petersburg, Russian Federation, 190121
- St. Nicholas the Wonder Worker Psychiatric Hospital
-
Saint Petersburg, Russian Federation, 199004
- City Narcology Hospital
-
Samara, Russian Federation, 443016
- Samara Psychiatric Hospital
-
Saratov, Russian Federation, 410028
- Saratov City Clinical Hospital #2 n.a. V.I. Razumovsky
-
Saratov, Russian Federation, 410060
- Regional Clinical Psychiatric Hospital of St. Sofia
-
St. Petersburg, Russian Federation, 195176
- Psychoneurological Dispensary # 5
-
Voronezh, Russian Federation, 394052
- LION-MED
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Center of Serbia, Clinic for Psychiatry
-
Belgrade, Serbia, 11000
- Clinical Hospital Center Dr Dragisa Misovic
-
Gornja Toponica, Serbia, 18202
- Clinical Centre Nis, Clinic for Psychiatry
-
Kovin, Serbia, 26220
- Special hospital for psychiatric diseases "Kovin
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac , Clinic for Psychiatry
-
Nis, Serbia, 18000
- Centre for Mental Health Protecton, Clinical Center Nis
-
-
-
-
-
Kosice, Slovakia, 04017
- EPAMED s r.o.
-
Liptovsky Mikulas, Slovakia, 03123
- Liptovska nemocnice s poliklinikou MUDr. Ivana Stodolu, Psychiatricke oddelenie
-
Svidnik, Slovakia, 50474
- Centrum Zdravia R.B.K., s.r.o.
-
-
-
-
-
Durbanville,, South Africa, 7550
- Flexivest Fourteen Research Centre, Unit 1, Durbanville Health Center
-
-
-
-
-
Dnipro, Ukraine, 49005
- Regional Centre of Psychosomatic Disorders based on Psychoneurology Department, Communal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnykov
-
Kharkiv, Ukraine, 61091
- Institute of neurology, Psychiatry and Narcology of NAMS of Ukraine, MC "Neuron"
-
Kyiv, Ukraine, 01030
- Kyiv Railway Clinical Hospital № 1 of Branch "Health Center" of the Public joint stock company "Ukrainian Railway"
-
Stepanivka, Ukraine, 73488
- Kherson Regional Psychiatric Hospital Department # 3 and # 10 Kherson region,
-
Ternopil, Ukraine, 46027
- Ternopil Regional Communal Clinical Psychoneurological Hospital, psychiatric department # 2 (men), psychiatric department # 6 (women), Ternopil State Medical University n.a. I.Y. Gorbachevskyy, Chair of Psychiatry, Narcology and Medical Psychology
-
Vinnytsya, Ukraine, 21005
- Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko", Male Department #14, Female Department #15, Vinnytsya National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeutic
-
-
-
-
-
Blackpool, United Kingdom, FY2 0JH
- MAC Clinical Research- Blackpool
-
Liverpool, United Kingdom, L34 1BH
- MAC Clinical Research Ltd.-Liverpool
-
Manchester, United Kingdom, M13 9NQ
- MAC Clinical Research- Manchester
-
-
-
-
California
-
Garden Grove, California, United States, 90806
- CNS Network
-
Glendale, California, United States, 91206
- Behavioral Research Specialists
-
Irvine, California, United States, 92614
- Irvine Clinical Research
-
Lemon Grove, California, United States, 91945
- Synergy San Diego
-
Oakland, California, United States, 94607
- Pacific Research Partners, LLC
-
Orange, California, United States, 92868
- NRC Research Institute
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80910
- MCB Clinical Research Centers, LLC
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Clinical Neuroscience Solutions ( CNS Healthcare)-Jacksonville
-
Maitland, Florida, United States, 32751
- Meridien Research
-
Miami, Florida, United States, 33174
- Florida Research Center, Inc.
-
Orlando, Florida, United States, 32801
- CNS Health Care (Orlando)
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
Atlanta, Georgia, United States, 30328
- Synexus Clinical Research
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Great Lakes Clinical Trials
-
Libertyville, Illinois, United States, 60048
- Capstone Clinical Research
-
-
Kansas
-
Prairie Village, Kansas, United States, 66208
- Collective Medical Research, LLC
-
-
Massachusetts
-
Watertown, Massachusetts, United States, 02472
- Adams Clinical
-
-
New York
-
Brooklyn, New York, United States, 11229
- Integrative Clinical Trials
-
Brooklyn, New York, United States, 11235
- Social Psychiatry Research Institute (SPRI)
-
New York, New York, United States, 10128
- The Medical Research Network, LLC
-
New York, New York, United States, 10029
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai
-
Rochester, New York, United States, 14618
- Finger Lakes Clinical Research
-
-
Ohio
-
Garfield Heights, Ohio, United States, 44125
- Charak Clinical Research Center
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Research Network (Oregon) Inc.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 26464
- Coastal Carolina Research Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Research Strategies of Memphis, LLC
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions CNS Healthcare
-
-
Texas
-
Dallas, Texas, United States, 75231
- Future Search Trials of Dallas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas, Inc.
-
Wichita Falls, Texas, United States, 76309
- Grayline Research Center
-
-
Wisconsin
-
Waukesha, Wisconsin, United States, 53188
- IPC Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Completed the antecedent study, Study ACP-103-054 or Study ACP-103-059
- May benefit from longer term therapy with open-label pimavanserin treatment
- If the subject is female, she must not be pregnant or breastfeeding. She must also be of nonchildbearing potential OR must agree to use acceptable methods of contraception
Exclusion Criteria:
- Is determined to be inappropriate for the study
- Has developed neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical or mental disorder, including cancer or malignancies that would affect the patient's ability to participate in the program
Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Drug - pimavanserin
Pimavanserin 34 mg tablets
|
Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment-emergent Adverse Events (TEAEs)
Time Frame: 52 weeks
|
Number of patients with treatment emergent AEs
|
52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pimavanserin
Other Study ID Numbers
Other Study ID Numbers
- ACP-103-055
- 2018-003252-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.